阿托伐他汀对血脂正常高血压患者ABI及HCY的影响  

Influence of atorvastatin on ABI and HCY in essential hypertensives with normal lipidemia

作　　者：孙国锋[1] 陈图刚[1] 谭维羚[1] 马战清[1] 钟志英[1] 

机构地区：[1]南昌大学第四附属医院心内科,南昌330000

出　　处：《江西医药》2015年第10期998-1001,共4页Jiangxi Medical Journal

摘　　要：目的观察阿托伐他汀对血脂正常的原发性高血压患者ankle-brachial index(ABI)及homocysteine(HCY)影响。方法血脂正常的原发性高血压患者130例随机分为对照组(n=63)和治疗组(n=67,阿托伐他汀20mg,每晚1次),疗程均为6个月。入选前所有患者经服用降压药物后血压控制在140/90mm Hg以下至少4周,观察ABI、HCY在治疗前后的变化。结果治疗6月末时,阿托伐他汀组治疗6月前后,ABI、HCY均有统计学差异(均P<0.05)。对照组治疗前后ABI、HCY的差异均无统计学意义(P>0.05)。结论阿托伐他汀可升高ABI,降低HCY,改善原发性高血压患者发生心脑血管疾病并发症的风险。Objective To observe the effect of atorvastatin on the serum homocysteine and ankle brachial index（ABI） in essential hypertensives with normal lipidemia. Methods One hundred and thirty essential hypertensives with normal lipidemia regularly taking anti-hypertension drugs were randomly divided into control group（n=63） and atorvastatin group（n=67） and treated for 6months. ABI and HCY were measured before and after treatment. Results No change of all measurements in control group was found after treatment. In atorvastatin group,however,ABI is increased,HCY is decreased（P〈0.05）. Conclusions Atorvastatin can rise ABI,reduce HCY,improve risk of complication in hypertensives.

关 键 词：阿托伐他汀 高血压 同型半胱氨酸 踝臂指数 

分 类 号：R544.1[医药卫生—心血管疾病]